厄贝沙坦联合黄葵胶囊治疗糖尿病肾病轻中度蛋白尿的临床效果观察

Clinical observation of irbesartan combined with ambrette capsule fotreatmenof mild-to.moderate proteinuriin type 2 diabetinephropathy

目的观察厄贝沙坦联合黄葵胶囊治疗2型糖尿病肾病（DN）轻中度蛋白尿的临床效果。方法选取符合WH01999年颁布的糖尿病诊断标准及DN诊断标准的46例DN患者，应用随机数字表分为治疗组23例和对照组23例。对照组给予常规口服降糖药物、调脂、钙拮抗剂降压及饮食控制等治疗；治疗组在对照组常规治疗基础上，给予厄贝沙坦75mg，每日1次，黄葵胶囊5粒，每日3次，口服治疗。治疗观察时间均为8周。分别于治疗前及治疗后8周检测24h尿蛋白定量、尿素氮（BUN）、血肌酐（SCr）、C反应蛋白（CRP）等。结果治疗8周后，治疗组总有效率87．O％（20／23）明显优于对照组52．2％（12／23），差异有统计学意义（2=6．571，P〈0．05）。治疗组治疗后CRP[（11．7±O．9）mg／L降至（5．8±0．3）mg／L]，相比于对照组[（10．1±0．6）mg／L降至（9．8±0．4）mg／L]显著下降，差异有统计学意义（t=4．681，P〈0．05）。结论厄贝沙坦联合黄葵胶囊可以明显降低尿蛋白，对微炎症状态也具有一定的调节作用。

Objective To observe the clinical effectof irbesartan combined with ambrette capsule fotreatmenof mild-to-moderate proteinuriin type 2 diabetinephropathy. MethodFoutty-six patientwith diabetinephropathy （DN）, who meethe diagnosticriterifodiabeteand DN diagnosticriteriwhich WHO promulgated in 1999 years, were randomly divided into control group （ n = 23 ） and treatmengroup （ n = 23 ）Patientin control group were administrated conventional hypoglycemidrugs, lipid, calcium antagoniststep- down and diecontrol, while in treatmengroup were administrated irbesartan （75 mg, 1 times/d） combined with ambrette capsule （5 pills, 3 times/d） on thibasis. Both the treatmenduration wa8 weeks. Urine protein, blood urenitrogen （BUN） ,serum creatinine （SCr） and reactive protein（CRP） were measured respectively before treatmenand 8 weekaftetreatment. ResultAfte8 weektreatment, the total effective rate in treatmengroup wa87.0% （20/23）, highethan thaof control group（52. 2% （ 12/23 ） ;X2 = 6. 571, P 〈 0. 05 ）. The CRP had decreased significantly in treatmengroup （ from （ 11.7 ±0. 9 ） mg/L to （ 5.8 ± 0. 3 ） mg/L） which compared with control group（from （ 10. 1 ±0. 6） mg/Lto （9.8 ±0. 4） mg/L;P 〈0. 05）. BuBUN and Schad no significandifference compared with pre-treatmen（ P 〉 0. 05 ） . Conclusion Irbesartan combine with ambrette capsule can significantly decrease the urine protein and regulate on the micro-inflammatory state. Iiworthy of popularization and application.